Morgan Stanley keeps Overweight ratings and lifts targets on four stocks
Morgan Stanley reaffirmed Overweight ratings on General Dynamics, Jazz, IDEXX and Hinge Health and raised their price targets, TradingView reports.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, Morgan Stanley kept Overweight ratings on four companies at once and raised their price targets. For General Dynamics, the target rose to $480 from $465, a 3.2% increase. Measured from the Nov 2 close of $373.46, that implies a 28.5% gain. Jazz Pharmaceuticals' target went up to $319 from $314 (+1.6%), IDEXX Laboratories' to $810 from $805 (+0.6%), and Hinge Health's to $131 from $117 (+12.0%).
For General Dynamics, other recent notes over the past 30 days set targets between $380 and $400.
why it matters
Changes like these reflect the view of a single brokerage and rarely move the broader market. For investors they matter mainly as one piece of the wider picture across sectors.
tags
instruments
sources
- Morgan Stanley maintains General Dynamics at Overweight, raises price target to $480 from $465 — TradingView, 3 November 2026 at 17:33 UTC
- Morgan Stanley maintains Jazz Pharmaceuticals at Overweight, raises price target to $319 from $314 — TradingView, 3 November 2026 at 17:35 UTC
- Morgan Stanley maintains IDEXX Laboratories at Overweight, raises price target to $810 from $805 — TradingView, 3 November 2026 at 17:34 UTC
- Morgan Stanley maintains Hinge Health at Overweight, raises price target to $131 from $117 — TradingView, 3 November 2026 at 17:33 UTC
- Morgan Stanley maintains Toll Brothers at Overweight, raises price target to $170 from $159 — TradingView, 3 November 2026 at 17:42 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗